JPWO2022040128A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022040128A5
JPWO2022040128A5 JP2023511947A JP2023511947A JPWO2022040128A5 JP WO2022040128 A5 JPWO2022040128 A5 JP WO2022040128A5 JP 2023511947 A JP2023511947 A JP 2023511947A JP 2023511947 A JP2023511947 A JP 2023511947A JP WO2022040128 A5 JPWO2022040128 A5 JP WO2022040128A5
Authority
JP
Japan
Prior art keywords
seq
sdcdr2
sdcdr1
sdcdr3
sdabd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023511947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538366A (ja
JP2023538366A5 (https=
JP7832926B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046217 external-priority patent/WO2022040128A2/en
Publication of JP2023538366A publication Critical patent/JP2023538366A/ja
Publication of JPWO2022040128A5 publication Critical patent/JPWO2022040128A5/ja
Publication of JP2023538366A5 publication Critical patent/JP2023538366A5/ja
Application granted granted Critical
Publication of JP7832926B2 publication Critical patent/JP7832926B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023511947A 2020-08-17 2021-08-17 制約され、条件付きで活性化された結合タンパク質 Active JP7832926B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066565P 2020-08-17 2020-08-17
US63/066,565 2020-08-17
PCT/US2021/046217 WO2022040128A2 (en) 2020-08-17 2021-08-17 Constrained conditionally activated binding proteins

Publications (4)

Publication Number Publication Date
JP2023538366A JP2023538366A (ja) 2023-09-07
JPWO2022040128A5 true JPWO2022040128A5 (https=) 2024-08-22
JP2023538366A5 JP2023538366A5 (https=) 2024-08-22
JP7832926B2 JP7832926B2 (ja) 2026-03-18

Family

ID=77655705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023511947A Active JP7832926B2 (ja) 2020-08-17 2021-08-17 制約され、条件付きで活性化された結合タンパク質

Country Status (16)

Country Link
US (1) US20240026011A1 (https=)
EP (1) EP4196503A2 (https=)
JP (1) JP7832926B2 (https=)
KR (1) KR20230048146A (https=)
CN (1) CN116419925A (https=)
AR (1) AR123266A1 (https=)
AU (1) AU2021329290A1 (https=)
CA (1) CA3191431A1 (https=)
CL (1) CL2023000477A1 (https=)
CO (1) CO2023002164A2 (https=)
EC (1) ECSP23018458A (https=)
IL (1) IL300598A (https=)
MX (1) MX2023002002A (https=)
PE (1) PE20230856A1 (https=)
TW (1) TW202214707A (https=)
WO (1) WO2022040128A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
IL302613B2 (en) 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
WO2023164551A1 (en) * 2022-02-23 2023-08-31 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
WO2024040228A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding proteins
WO2024040220A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding fusion proteins
EP4583921A1 (en) * 2022-09-07 2025-07-16 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Anti-trop2/egfr antibodies and uses thereof
WO2024147897A2 (en) * 2023-01-05 2024-07-11 Harpoon Therapeutics, Inc. Trop2 targeting trispecific protein for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2014010482A (en) 2011-08-17 2014-04-28 Glaxo Group Ltd Modified proteins and peptides
KR20230041739A (ko) 2016-03-08 2023-03-24 매버릭 테라퓨틱스, 인크. 유도성 결합 단백질 및 사용 방법
IL302613B2 (en) * 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
WO2020181140A1 (en) * 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins

Similar Documents

Publication Publication Date Title
TWI812637B (zh) 限制性條件性活化之結合蛋白
KR100484084B1 (ko) 키메라성 폴리펩타이드, 이의 제조 방법 및 용도
CN107922486B (zh) 异源二聚体多特异性抗体形式
CA3065868C (en) Novel hetero-dimeric multi-specific antibody format
JP2022065174A5 (https=)
CN114390938B (zh) 受约束的条件性活化的结合蛋白
JP2019513014A5 (https=)
JPWO2019234220A5 (https=)
JP7832926B2 (ja) 制約され、条件付きで活性化された結合タンパク質
GB2518221A (en) Tetravalent antigen-binding protein molecule
JP2025527303A (ja) Ｉｌ－１８融合タンパク質およびｉｌ－１８を産生する方法
CN105229036A (zh) 在疏水性相互作用位点内引入了静电相互作用的蛋白及其制备方法
JP7847284B1 (ja) 上皮増殖因子受容体を標的とする組成物並びにその製造方法及び使用方法
JPWO2020181145A5 (https=)
JPWO2022040128A5 (https=)
US20230340159A1 (en) Constrained conditionally activated binding proteins
JPWO2020181140A5 (https=)
JPWO2023141713A5 (https=)
US11028132B1 (en) Half-life optimized linker composition
CN121949565A (zh) 靶向表皮生长因子受体的组合物及其制备和使用方法
JP2026064000A (ja) 抗原結合分子
Kirkendoll et al. Immobilized enzyme-assisted production of recombinant P113 peptide
JP2023057069A5 (https=)
JP2026505450A (ja) 一本鎖抗体断片の化学合成法およびそれにより得られる物
AU2022237943A1 (en) Hybrid molecule comprising an antibody fc fragment and at least one fibrin-derived citrullinated peptide, and uses thereof